Navigation Links
Transduction in Medical Technology

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

... anticancer agent that modulates Akt and several other important signal transduction pathways. Keryx is currently in the process of finalizing late-stage ... survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways ...

Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting

... to the retina. This suggests that inhibiting the PI3K/Akt/mTor signal transduction pathway by Palomid 529 may be neuroprotective to photoreceptors and ... one of which, TORC1, regulates cell growth by acting on the signal transduction protein S6K, while the other, TORC2, regulates cell survival through Akt. ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... oral anti-cancer agent that modulates Akt and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways ... survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways ...

Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364

... time." CPSI-2364 is a chemically-modified form of the synthetic guanylhydrozone, semapimod. Semapimod has been shown to inhibit the signal transduction pathways that lead to the production of nitric oxide and important pro-inflammatory cytokines, including TNF-alpha, IL-1, IL-6, and IL-8. Semapimod ...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell ...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell ...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

... PI3K/PTEN pathway. About PI3 Kinase Phosphatidylinositol 3 kinases (PI3K) are involved in one of the major pathways of intracellular signal transduction and are important in controlling cell growth/angiogenesis, differentiation, proliferation and survival/apoptosis. Dysregulation of the PI3 kinase ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

... agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell ...

Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting

... has utilized its platform technologies to identify highly selective inhibitors of therapeutically relevant targets that are involved in signal transduction and cell cycle control. CONTACT: Lyn Dyster, Vice President, Research Operations of Kinex Pharmaceuticals, +1-716-881-8984 ...

Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research

... Southern California ; "Targeting the PI3K Pathway in Women's Cancers" / Leader: Lewis C. Cantley, Ph.D., Chief of the Division of Signal transduction at Beth Israel Deaconess Medical Center; Co-Leaders: Charles L. Sawyers, M.D., Director of the Human Oncology and Pathogenesis Program at Memorial ...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

... PI3K/PTEN pathway. About PI3 Kinase Phosphatidylinositol 3 kinases (PI3K) are involved in one of the major pathways of intracellular signal transduction and are important in controlling cell growth/angiogenesis, differentiation, proliferation and survival/apoptosis. Dysregulation of the PI3 kinase ...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

... various solid tumors and hematological cancers. The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. BIBW 2992 entered Phase IIb/III clinical development in NSCLC earlier in 2008 and was granted Fast ...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

... agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell ...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia

... PIM kinases are strong survival factors and can induce progression of the cell cycle, inhibition of apoptosis, and modulation of other signal transduction pathways. Therefore, SGI-1776 can induce cell death in cancer cells expressing PIM kinases and promote sensitivity of cancer cells to treatment with ...

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology

... agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell ...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

... agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell ...

St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity

... insight into how autoimmune diseases start. "One implication of our findings is that a relatively small defect in the efficiency of signal transduction through the T cell receptor could give rise to a subtle failing in negative selection, which gives rise over a long period of time to a few overly ...

Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases

... being held this week in San Diego, CA. Researchers conducted studies with PCI-32765 examining the downstream signaling events in the BCR signal transduction pathways. In vitro drug treatment of B-cell lymphomas blocked BCR mediated signaling and in vivo drug treatment of lymphoma-bearing animal models ...

Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial

... agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell ...

St. Jude Finds Signaling System That Halts the Growth of a Childhood Brain Cancer

... supported by the National Institutes of Health, a Cancer Core Grant, La Fondation pour la Recherche Medicale, the Gephardt Endowed Fellowship Signal transduction and ALSAC. St. Jude Children's Research Hospital St. Jude Children's Research Hospital is internationally recognized for its pioneering work in ...

Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint

... agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell ...

Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial

... (perifosine), a novel, first-in- class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition ...

Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology

... (KRX-0401) Mechanism of Action and Profile Perifosine has been shown to inhibit or otherwise modify signaling through a number of different signal transduction pathways including Akt, MAPK, and JNK. Akt isoforms have been found to be overexpressed in renal, breast, prostate, and pancreatic cancers. Elevated ...

Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data

... (perifosine), a novel, first-in- class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition ...

Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium

... (KRX-0401) Mechanism of Action and Profile Perifosine has been shown to inhibit or otherwise modify signaling through a number of different signal transduction pathways including Akt, MAPK, and JNK. Akt isoforms have been found to be overexpressed in renal, breast, prostate, and pancreatic cancers. Elevated ...

Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma

... KRX-0401 (Perifosine) KRX-0401 (perifosine) is a novel, first-in-class, oral anticancer agent that modulates AKT and a number of other key signal transduction pathways, including the MAPK and JNK pathways all of which are pathways associated with programmed cell death, cell growth, cell differentiation and ...

Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference

... (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in- licensing and acquisition ...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

... oral anticancer agent that modulates AKT and a number of other key signal transduction pathways, including the MAPK and JNK pathways all of which are pathways ... associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for ...

Immunosuppressant Drug Prevents Tobacco Induced Lung Cancer in Mice

... provide an exciting link between exposure to an important tobacco carcinogen, NNK, and mTOR, said Phillip A. Dennis, M.D., Ph.D., head, Signal transduction Section of NCI's Center for Cancer Research. The critical question is whether this approach would be safe and effective in smokers at high risk ...

Gentium's Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting

... of Defibrotide (450 mg/kg daily) significantly reduced tumor angiogenesis, as measured by micro-vascular density at day 7 (p=0.035). The signal transduction mechanism of Defibrotide as demonstrated by Western blotting results show that Defibrotide reduces phosphorylation-activation of p70S6 kinase, which ...

ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR

... Increase in intra-cellular Reactive Oxygen Species enhances this effect on mitochondrial functions and consequently the activation of the signal transduction pathway leading to apoptosis. In addition, ZIO-101 interrupts the cell cycle at the G2/M phase of tumor cells inducing cell death through this ...

New Pfizer Oncology Data Across Numerous Cancer Types to be Presented at ASCO

... portfolio, focused in three areas of discovery: anti-angiogenesis, signal transduction and immuno-oncology. Anti-Angiogenesis SUTENT(R) (sunitinib ... efficacy and safety of axitinib in advanced, refractory NSCLC. Signal transduction -- A phase II trial evaluated the safety and efficacy of ...

AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting

... network. About Perifosine (KRX-0401) Perifosine is a novel, first-in-class, oral anti-cancer agent that modulates several key signal transduction pathways, including Akt, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated single ...

Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology

... binding formats such as Duocalins(R) have significant potential in targeting cell surface molecules in disease, mediating agonistic effects on signal transduction pathways or inducing enhanced internalization effects via binding and clustering of cell surface receptors. The data will be presented for the ...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois

... including KRX-0401, a novel, first-in- class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and ...

ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

... Increase in intra-cellular Reactive Oxygen Species enhances this effect on mitochondrial functions and consequently the activation of the signal transduction pathway leading to apoptosis. In addition, darinaparsin interrupts the cell cycle at the G2/M phase of tumor cells inducing cell death through this ...

Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

... mso-special-character: line-break" clear="all" /> About HMPL-004 HMPL-004 acts on multiple cellular targets in the inflammatory signal transduction pathways resulting in suppressed inflammation cytokine expression including TNF-?, IL-1? and IL-6. HMPL-004 was demonstrated to inhibit TNF-? ...
Other Contents
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
(Date:3/2/2015)... March 02, 2015 Burns Engineering's ... calibration for Secondary Standard Platinum Resistance Thermometers (SSPRTs) ... business days or less . . . guaranteed. ... ® Accredited (Lab Code 200706-0), ISO 9001 and ... Temperature range is -196°C to 500°C, both ITS-90 ...
(Date:3/2/2015)... 2015 The minimally invasive surgical ... CAGR of 6.1% to reach $14,133.0 million by ... Factors such as advantages of minimally invasive surgeries ... to minimally invasive surgeries and increasing number of ... the global minimally invasive surgical instruments market. , ...
(Date:3/2/2015)... Four Seasons Resort Maui at Wailea, the ... this year, having officially opened its doors on March 2, ... honoring over 70 employees who started on Day 1 and ... approximately 400 original employees. The celebration will be a ... , This Four Seasons flagship resort, the first resort ...
(Date:3/2/2015)... March 02, 2015 The Alliance for ... safety expert Mark Chubb to serve as chief safety ... operations and training in Bangladesh and guide remediation efforts ... , “Mark will ensure that the Alliance continues to ... programs for Bangladesh garment workers,” said Alliance Independent Chair ...
(Date:3/2/2015)... Secura Consultants announced today the ... Protective Insurance Group of Birmingham, AL (First Protective). ... affiliated advisors to access the enhanced disability income ... delivers. , Secura Consultants, based in ... design and implementation of insured income protection programs. ...
Breaking Medicine News(10 mins):Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2
Other TagsOther Tags